# Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

> **NCT01344876** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** OPB-51602

## Key facts

- **NCT ID:** NCT01344876
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01344876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01344876, "Phase I Study of OPB-51602 in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT01344876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*